

Primary Care Adult Headache Management Pathway

Version 1.2 – October 2024

VERSION CONTROL		
Version	Date	Amendments made
Version 1.0	October 2018	Reformatted version 8 of the North West Headache Management Guideline for Adults to match other LMMG guidelines. Amended clinical content in line with NICE OTC guidance.
Version 1.1	April 2024	Updated in conjunction with LTH neurology. MHRA alert for topiramate added. Valproate/valproic acid is not to be prescribed for migraine prophylaxis added at the request of LSCMMG. Reference to oxygen for cluster headache removed at the request of LSCMMG.
Version 1.2	October 2024	Atogepant added as per NICE TA 973 and amendments made to section on GCA.

Page

3 Adult Headache Management Pathway


4 Adult Headache Management Pathway – additional information

5 Adult Headache Management Pathway – additional information

7 Bibliography

Adult Headache Management Pathway

Additional information on headache types – page 2 and 3



Box 1 – Migraine – see page 5 for prophylaxis

- Throbbing pain lasting hours to 3 days
- Sensitivity to stimuli: light and sound, sometimes smells
- Nausea
- Aggravated by physical activity (prefers to lie or sit still)
- Aura, if present, evolves slowly (in contrast to TIA or stroke) and lasts minutes to hours.

Chronic migraine (15 or more headache days per month, of which 8 or more are migraine)

Education and a better understanding of the condition can be facilitated by directing patients to:

- www.nhs.uk/conditions/headaches/ OR
- www.migrainetrust.org

Explain the risk of medication overuse headaches to people using acute treatments (particularly any use of opiates and triptans >10 days a month)

If relevant, consider stopping combined oral contraceptives (note: combined oral contraceptives are contraindicated in migraine with aura)

Lifestyle modification e.g. adequate hydration, sleep, exercise, STOP caffeine, avoid triggers and address psychosocial factors if necessary.

Consider using a headache diary to record the frequency, duration and severity of headaches and to monitor the effectiveness of headache interventions. Can be used as a basis for discussion about headache disorder and impact: <https://migrainetrust.org/wp-content/uploads/2021/06/The-Migraine-Trust-headache-diary-Word.docx>

Giant Cell Arteritis

- Incidence 2/10,000 per year
- Consider with presentations of new headache in people > 50 years old
- ESR can be normal in 10% - check CRP as well

Symptoms may include: jaw or tongue claudication, scalp tenderness, visual disturbance, temporal artery: prominent, tender, diminished pulse; other cranial nerve palsies, limb claudication

Many headaches respond to high-dose steroids. **However**, do not use the response as the sole diagnostic factor.

Urgent Referral to:

Rheumatology if GCA suspected

If visual symptoms same day referral to ophthalmology

Please consult your local GCA referral pathway

2 Week Wait – suspected cancer referral

Headache with features of raised intracranial pressure:

- Actively wakes a patient from sleep, but not migraine or cluster
- Precipitated by Valsalva manoeuvres e.g. cough, straining at stool
- Papilloedema

Other symptoms of raised ICP headache include:

- Headache is present upon waking and easing once up (analgesic overuse can cause this pattern) and worse when recumbent.
- Pulse synchronous tinnitus
- Episodes of transient visual loss when changing posture e.g. on standing
- Vomiting – significance should be judged in context as nausea and vomiting are features of migraine Headache with new-onset seizures
- Headache with persistent new or progressive neurological deficit

Emergency symptoms or signs

Thunderclap onset
Accelerated or malignant hypertension
Papilloedema
Acute onset with focal neurological signs
Head trauma with raised ICP headache
Photophobia + nuchal rigidity + fever +/- rash
Reduced consciousness
Acute red eye ?acute angle closure glaucoma

New onset headache in:

3rd trimester pregnancy or early postpartum
Significant head injury – especially elderly patients with alcohol dependency or patients on anticoagulants

Red flags

- Headache rapidly increasing in severity and frequency despite appropriate treatment
- Undifferentiated headache (not migraine or tension headache) of recent origin and present for > 8 weeks
- Recurrent headaches triggered by exertion
- New onset headache in : > 50 years old (consider giant cell arteritis; CNS malignancy); immunosuppressed or HIV or known malignancy

Migraine prophylaxis

Please note: Sodium valproate and valproic acid should **NOT** be used for migraine prophylaxis

The decision to start prophylaxis should be based on the impact of the migraine on the patient's quality of life (e.g. >4 /month). The choice of treatment depends on patient preference, drug interactions and other co-morbidities. Treatment should be started at a low dose and gradually increased to the maximum effective and tolerated dose.

Trial for 3 months titrating dose according to response before judging efficacy

First-line options – to be considered in primary care:

Propranolol MR 80mg once daily, increased gradually to a maximum of 240mg once daily.

NICE CG150 - People with depression and migraine could be at an increased risk of using propranolol for self-harm. Use caution when prescribing propranolol, in line with the [Healthcare Safety Investigation Branch's report on the under-recognised risk of harm from propranolol](#).

Amitriptyline 10mg at night, increased in 10mg every fortnight as necessary to 100mg at night [unlicensed, but standard practice – see NICE CKS: Migraine]

Candesartan 2mg once daily, increased gradually to a **maximum** of 16mg daily.

Advise patients that riboflavin 400mg once daily may be effective in reducing migraine frequency and intensity for some people – purchase OTC (avoid if planning a pregnancy or pregnant).

First-line options only in those not of childbearing potential – to be considered in primary care:

Topiramate 25mg once daily, increased by 25mg every fortnight as necessary to 50mg twice daily.

Topiramate - contraindicated for use in pregnancy and women of childbearing potential

Topiramate can be considered first-line in primary care for the prevention of migraine for some patients. However, the MHRA have published guidance in June 2024. In summary:

- Topiramate is now **contraindicated for use in pregnancy and women of childbearing potential** unless specific conditions of a Pregnancy Prevention Programme are met.

- The use of topiramate during pregnancy has been linked to significant risks, including congenital malformations, low birth weight, and potential neurodevelopmental disorders such as intellectual disability, autism spectrum disorder, and ADHD.
- Healthcare professionals will receive materials, including guides, risk awareness forms, and patient cards, to support patient discussions and the implementation of the Pregnancy Prevention Programme. A healthcare professionals guide can be accessed via:

[Topiramate \(Topamax\): introduction of new safety measures, including a Pregnancy Prevention Programme - GOV.UK \(www.gov.uk\)](https://www.medicines.org.uk/emc/rmm/3079/Document)
<https://www.medicines.org.uk/emc/rmm/3079/Document>

Second line options – on the recommendation of secondary care:

Rimegepant 75mg on alternate days

Eligible for episodic migraine (as per NICE TA 906):

Between 4 and 15 migraine attacks per month, *and*

At least 3 preventative medications, at suitable dose/duration, have not worked, *and*

Recommended by a specialist – LSCMMG RAG rating Amber 0

Second line options – on the recommendation of secondary care continued:

Atogepant 60mg ONCE a day

Eligible for preventing migraine (as per NICE TA 973):

At least 4 migraine days per month, *and*

At least 3 preventative medications, at suitable dose/duration, have not worked, *and*

Recommended by a specialist – LSCMMG RAG rating Amber 0

Please note: if people with the condition and their healthcare professionals consider atogepant or rimegepant to be one of a range of suitable treatments, after discussing the advantages and disadvantages of all the options, use the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.

Cluster Headache

More common in men

Severe pain lasting 30-120 minutes Unilateral, side locked

Agitation, pacing (note: migraine patients prefer to keep still)

Unilateral cranial autonomic features: tearing, red conjunctive, ptosis, miosis nasal stuffiness

Acute treatments:

Offer a subcutaneous triptan (nasal triptan can be considered [unlicensed indication]).

Do not offer paracetamol, NSAIDS, opioids, ergots or oral triptans

Tension-Type Headache

Band like ache

Mostly featureless

Can have mild photo OR phonophobia but NO nausea

Treatment:

Aspirin, paracetamol or an NSAID. Do **not** offer opioids

Tension-type headache prophylaxis

Amitriptyline, following the same dose schedule as for migraine above.

Consider acupuncture, if available.

Analgesic Overuse Headache

Can be migrainous and/or tension-type

At risk if analgesic intake ≥ 15 days per month (opiates ≥ 10 days) for ≥ 3 months OR triptan intake ≥ 10 days per month for ≥ 3 months

Treatment: Stop analgesic or triptan for 3 months

BIBLIOGRAPHY

1. NHS North West Coast Strategic Clinical Network. North West Headache Management Guideline for Adults, Version 8. September 2015 (Basis of original guidance document)
2. National Institute for Health and Care Excellence. NICE clinical guideline 150: Headaches in over 12s: diagnosis and management., 2012 (updated 2021). Accessed via: <https://www.nice.org.uk/guidance/cg150> [accessed online: April 2024].
3. National Institute for Health and Care Excellence. NICE Technology Appraisal 919: Rimegepant for preventing migraine. 5th July 2023. Accessed via: <https://www.nice.org.uk/guidance/ta919> [accessed online: April 2024].
4. National Institute for Health and Care Excellence. NICE Technology Appraisal 906: Rimegepant for treating migraine. 18th October 2023. Accessed via: <https://www.nice.org.uk/guidance/ta906> [accessed online: April 2024].
5. National Institute for Health and Care Excellence. NICE Technology Appraisal 973: Atogepant for preventing migraine. 15th May 2024. Accessed via: <https://www.nice.org.uk/guidance/ta973> [accessed online: June 2024].
6. National Institute for Health and Clinical Excellence. Clinical Knowledge Summary: Migraine. Lasted update: September 2022. Accessed via <https://cks.nice.org.uk/topics/migraine/> [accessed online: April 2024].

©Midlands and Lancashire Commissioning Support Unit, 2024.

The information contained herein may be superseded in due course. All rights reserved.
Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.

Midlands and Lancashire Commissioning Support Unit,
Jubilee House, Lancashire Business Park, Leyland, PR26 6TR
Tel: 01772 644 400 | www.midlandsandlancashirecsu.nhs.uk